Citations (25)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (6)
Karen M. MacDonald, Abhishek Kavati, Benjamin Ortiz, Abdulaziz Alhossan, Christopher S. Lee & Ivo Abraham. (2019) Short- and long-term real-world effectiveness of omalizumab in severe allergic asthma: systematic review of 42 studies published 2008-2018. Expert Review of Clinical Immunology 15:5, pages 553-569.
Read now
Read now
Giovanni Passalacqua, Andrea Matucci, Alessandra Vultaggio, Diego Bagnasco, Marcello Mincarini, Enrico Maggi & Giorgio Walter Canonica. (2016) The safety of monoclonal antibodies in asthma. Expert Opinion on Drug Safety 15:8, pages 1087-1095.
Read now
Read now
Evgenia Papathanassiou, Stelios Loukides & Petros Bakakos. (2016) Severe asthma: anti-IgE or anti-IL-5?. European Clinical Respiratory Journal 3:1.
Read now
Read now
Torsten Zuberbier & Marcus Maurer. (2015) Omalizumab for the treatment of chronic urticaria. Expert Review of Clinical Immunology 11:2, pages 171-180.
Read now
Read now
Girolamo Pelaia, Luca Gallelli, Teresa Renda, Pasquale Romeo, Maria Teresa Busceti, Rosa Daniela Grembiale, Rosario Maselli, Serafino Antonio Marsico & Alessandro Vatrella. (2011) Update on optimal use of omalizumab in management of asthma. Journal of Asthma and Allergy 4, pages 49-59.
Read now
Read now
Cailong Fang, Chris J Corrigan & Sun Ying. (2011) Identifying and testing potential new anti-asthma agents. Expert Opinion on Drug Discovery 6:10, pages 1027-1044.
Read now
Read now
Articles from other publishers (19)
Koichiro Asano, Kazuya Sumi, Hajime Yoshisue, Noriko Nakamura, Makoto Nagasaki, Takayoshi Sasajima & Hisako Matsumoto. (2020) Real-life safety and efficacy of omalizumab in Japanese patients with severe allergic asthma who were subjected to dosing table revision or expansion: A post-marketing surveillance. Pulmonary Pharmacology & Therapeutics 64, pages 101950.
Crossref
Crossref
Jason Ho Seung Kim, Jorge R. Georgakopoulos & Jensen Yeung. (2020) Impact of COVID-19 on Patient-Initiated Discontinuation of Omalizumab in Two Academic Hospital Clinics at the University of Toronto. Journal of Cutaneous Medicine and Surgery 24:5, pages 534-535.
Crossref
Crossref
Girolamo Pelaia, Alessandro Vatrella & Rosario MaselliGirolamo Pelaia, Alessandro Vatrella & Rosario Maselli. 2017. Asthma: Targeted Biological Therapies. Asthma: Targeted Biological Therapies
27
49
.
Marie Jachiet, Maxime Samson, Vincent Cottin, Jean-Emmanuel Kahn, Guillaume Le Guenno, Philippe Bonniaud, Hervé Devilliers, Laurence Bouillet, Anne Gondouin, Fatma Makhlouf, Nadine Meaux-Ruault, Helder Gil, Boris Bienvenu, André Coste, Matthieu Groh, Violaine Giraud, Stéphane Dominique, Bertrand Godeau, Xavier Puéchal, Chahera Khouatra, Marc Ruivard, Claire Le Jeunne, Luc Mouthon, Loïc Guillevin & Benjamin Terrier. (2016) Anti-IgE Monoclonal Antibody (Omalizumab) in Refractory and Relapsing Eosinophilic Granulomatosis With Polyangiitis (Churg-Strauss): Data on Seventeen Patients. Arthritis & Rheumatology 68:9, pages 2274-2282.
Crossref
Crossref
Eileen Wang & Flavia C.L. Hoyte. (2016) Traditional Therapies for Severe Asthma. Immunology and Allergy Clinics of North America 36:3, pages 581-608.
Crossref
Crossref
I. Abraham, A. Alhossan, C. S. Lee, H. Kutbi & K. MacDonald. (2016) ‘Real-life’ effectiveness studies of omalizumab in adult patients with severe allergic asthma: systematic review. Allergy 71:5, pages 593-610.
Crossref
Crossref
Benjamin D. Goldstein, Arnold I. Caplan & Tracey L. Bonfield. 2016. Mesenchymal Stem Cells and Immunomodulation. Mesenchymal Stem Cells and Immunomodulation
7
24
.
Sarbjit S. Saini, Carsten Bindslev-Jensen, Marcus Maurer, Jean-Jacques Grob, Emel Bülbül Baskan, Mary S. Bradley, Janice Canvin, Abdelkader Rahmaoui, Panayiotis Georgiou, Oral Alpan, Sheldon Spector & Karin Rosén. (2015) Efficacy and Safety of Omalizumab in Patients with Chronic Idiopathic/Spontaneous Urticaria Who Remain Symptomatic on H 1 Antihistamines: A Randomized, Placebo-Controlled Study. Journal of Investigative Dermatology 135:1, pages 67-75.
Crossref
Crossref
Claus Kroegel & Martin Foerster. 2014. Handbook of Therapeutic Antibodies. Handbook of Therapeutic Antibodies
1775
1824
.
Sophia Tsabouri, Xanthippi Tseretopoulou, Konstantinos Priftis & Evangelia E. Ntzani. (2014) Omalizumab for the Treatment of Inadequately Controlled Allergic Rhinitis: A Systematic Review and Meta-Analysis of Randomized Clinical Trials. The Journal of Allergy and Clinical Immunology: In Practice 2:3, pages 332-340.e1.
Crossref
Crossref
Pınar Uysal, Esben Eller, Charlotte G. Mortz & Carsten Bindslev-Jensen. (2014) An algorithm for treating chronic urticaria with omalizumab: Dose interval should be individualized. Journal of Allergy and Clinical Immunology 133:3, pages 914-915.e2.
Crossref
Crossref
Miyoung Kim, Jeehye Maeng & Kyunglim Lee. (2013) Dimerization of TCTP and its clinical implications for allergy. Biochimie 95:4, pages 659-666.
Crossref
Crossref
Jennifer L. Ingram & Monica Kraft. (2012) IL-13 in asthma and allergic disease: Asthma phenotypes and targeted therapies. Journal of Allergy and Clinical Immunology 130:4, pages 829-842.
Crossref
Crossref
María del Carmen Vennera & César Picado. (2012) Patologías mediadas por la inmunoglobulina E: de la inmunoglobulina E al omalizumab. Inmunología 31:4, pages 119-126.
Crossref
Crossref
Pauline L Martin & Peter J Bugelski. (2012) Concordance of preclinical and clinical pharmacology and toxicology of monoclonal antibodies and fusion proteins: soluble targets. British Journal of Pharmacology 166:3, pages 806-822.
Crossref
Crossref
William Busse, Roland Buhl, Carlos Fernandez Vidaurre, Martin Blogg, Jin Zhu, Mark D. Eisner & Janice Canvin. (2012) Omalizumab and the risk of malignancy: Results from a pooled analysis. Journal of Allergy and Clinical Immunology 129:4, pages 983-989.e6.
Crossref
Crossref
Hoan Linh Banh, June Trevoy, Henry Pabst, Jeremy Beach & Dilini Vethanayagam. (2012) Persistent elevation of peripheral blood myeloid cell counts associated with omalizumab therapy. American Journal of Health-System Pharmacy 69:4, pages 302-306.
Crossref
Crossref
Neil C. ThomsonRekha Chaudhuri. (2012) Omalizumab: Clinical Use for the Management of Asthma. Clinical Medicine Insights: Circulatory, Respiratory and Pulmonary Medicine 6, pages CCRPM.S7793.
Crossref
Crossref
Kristin Kuhl & Nicola A. Hanania. (2012) Targeting IgE in asthma. Current Opinion in Pulmonary Medicine 18:1, pages 1-5.
Crossref
Crossref